This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

NCT06738277 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

DRUG: Bmab 1200 (Biosimilar Ustekinumab)

Sponsor

Biocon Biologics UK Ltd